This is a news story, published by Ars Technica, that relates primarily to Medicare news.
For more health policy news, you can click here:
more health policy newsFor more news from Ars Technica, you can click here:
more news from Ars TechnicaOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like this article about health policy, you might also like this article about
Medicare drug price negotiations. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest singularly astronomical drug prices news, pharmaceutical industry news, news about health policy, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
drug pricing reformsArs Technica
•82% Informative
Pharmaceutical Research and Manufacturers of America released two attacks on Medicare drug price negotiations this week .
PhRMA: Medicare negotiations could actually cost some seniors and people with disabilities slightly more in out-of-pocket costs.
Analysis relies on a key assumption that the federal government will set price limits using the highest possible estimate for maximum fair prices in 2026 .
VR Score
84
Informative language
84
Neutral language
29
Article tone
formal
Language
English
Language complexity
68
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
8
Source diversity
5
Affiliate links
no affiliate links